BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 28061437)

  • 1. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma.
    Fabrizio FP; Costantini M; Copetti M; la Torre A; Sparaneo A; Fontana A; Poeta L; Gallucci M; Sentinelli S; Graziano P; Parente P; Pompeo V; De Salvo L; Simone G; Papalia R; Picardo F; Balsamo T; Flammia GP; Trombetta D; Pantalone A; Kok K; Paranita F; Muscarella LA; Fazio VM
    Oncotarget; 2017 Feb; 8(7):11187-11198. PubMed ID: 28061437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic modifications but not genetic polymorphisms regulate KEAP1 expression in colorectal cancer.
    Gao L; Yuan F; Che G; Xiao X; Nie X; Wang Y; Jia J; Kong AN; Zhang L
    J Cell Biochem; 2019 Aug; 120(8):12311-12320. PubMed ID: 30825237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic versus Genetic Deregulation of the KEAP1/NRF2 Axis in Solid Tumors: Focus on Methylation and Noncoding RNAs.
    Fabrizio FP; Sparaneo A; Trombetta D; Muscarella LA
    Oxid Med Cell Longev; 2018; 2018():2492063. PubMed ID: 29643973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of Keap1 contributes to poor prognosis and Axitinib resistance of renal cell carcinoma via upregulation of Nrf2 expression.
    Huang H; Wu Y; Fu W; Wang X; Zhou L; Xu X; Huang F; Wu Y
    Int J Mol Med; 2019 May; 43(5):2044-2054. PubMed ID: 30896860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.
    Du Z; Li L; Huang X; Jin J; Huang S; Zhang Q; Tao Q
    Oncotarget; 2016 Apr; 7(16):21618-30. PubMed ID: 26943038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional and epigenetic characterization of the KRT19 gene in renal cell neoplasms.
    Paiva F; Duarte-Pereira S; Costa VL; Ramalho-Carvalho J; Patrício P; Ribeiro FR; Lobo F; Oliveira J; Jerónimo C; Henrique R
    DNA Cell Biol; 2011 Feb; 30(2):85-90. PubMed ID: 20874491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of KEAP1 Silencing on the Regulation of NRF2 Activity in Neuroendocrine Lung Tumors.
    Sparaneo A; Fabrizio FP; la Torre A; Graziano P; Di Maio M; Fontana A; Bisceglia M; Rossi A; Pizzolitto S; De Maglio G; Tancredi A; Grimaldi F; Balsamo T; Centra F; Manzorra MC; Trombetta D; Pantalone A; Bonfitto A; Maiello E; Fazio VM; Muscarella LA
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DPP9 Stabilizes NRF2 to Suppress Ferroptosis and Induce Sorafenib Resistance in Clear Cell Renal Cell Carcinoma.
    Chang K; Chen Y; Zhang X; Zhang W; Xu N; Zeng B; Wang Y; Feng T; Dai B; Xu F; Ye D; Wang C
    Cancer Res; 2023 Dec; 83(23):3940-3955. PubMed ID: 37713596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent epigenetic suppression of tumor suppressor gene glutathione peroxidase 3 by promoter hypermethylation and its clinical implication in clear cell renal cell carcinoma.
    Liu Q; Jin J; Ying J; Sun M; Cui Y; Zhang L; Xu B; Fan Y; Zhang Q
    Int J Mol Sci; 2015 May; 16(5):10636-49. PubMed ID: 25970749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypermethylation of the Keap1 gene inactivates its function, promotes Nrf2 nuclear accumulation, and is involved in arsenite-induced human keratinocyte transformation.
    Wang D; Ma Y; Yang X; Xu X; Zhao Y; Zhu Z; Wang X; Deng H; Li C; Gao F; Tong J; Yamanaka K; An Y
    Free Radic Biol Med; 2015 Dec; 89():209-19. PubMed ID: 26409248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deregulation of PAX2 expression in renal cell tumours: mechanisms and potential use in differential diagnosis.
    Patrício P; Ramalho-Carvalho J; Costa-Pinheiro P; Almeida M; Barros-Silva JD; Vieira J; Dias PC; Lobo F; Oliveira J; Teixeira MR; Henrique R; Jeronimo C
    J Cell Mol Med; 2013 Aug; 17(8):1048-58. PubMed ID: 23890189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma.
    Breault JE; Shiina H; Igawa M; Ribeiro-Filho LA; Deguchi M; Enokida H; Urakami S; Terashima M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):557-64. PubMed ID: 15701841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nrf2 gene mutation and single nucleotide polymorphism rs6721961 of the Nrf2 promoter region in renal cell cancer.
    Yamaguchi Y; Kamai T; Higashi S; Murakami S; Arai K; Shirataki H; Yoshida KI
    BMC Cancer; 2019 Nov; 19(1):1137. PubMed ID: 31752777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma.
    Nojima D; Nakajima K; Li LC; Franks J; Ribeiro-Filho L; Ishii N; Dahiya R
    Mol Carcinog; 2001 Sep; 32(1):19-27. PubMed ID: 11568972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
    Namani A; Matiur Rahaman M; Chen M; Tang X
    BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma.
    Dahl E; Wiesmann F; Woenckhaus M; Stoehr R; Wild PJ; Veeck J; Knüchel R; Klopocki E; Sauter G; Simon R; Wieland WF; Walter B; Denzinger S; Hartmann A; Hammerschmied CG
    Oncogene; 2007 Aug; 26(38):5680-91. PubMed ID: 17353908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MBD1 is an Epigenetic Regulator of KEAP1 in Pancreatic Cancer.
    Zhang B; Xu J; Li C; Shi S; Ji S; Xu W; Liu J; Jin K; Liang D; Liang C; Liu L; Liu C; Qin Y; Yu X
    Curr Mol Med; 2016; 16(4):404-11. PubMed ID: 26980696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma.
    Ooi A; Dykema K; Ansari A; Petillo D; Snider J; Kahnoski R; Anema J; Craig D; Carpten J; Teh BT; Furge KA
    Cancer Res; 2013 Apr; 73(7):2044-51. PubMed ID: 23365135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas.
    Zhao Q; Caballero OL; Davis ID; Jonasch E; Tamboli P; Yung WK; Weinstein JN; ; Strausberg RL; Yao J
    Clin Cancer Res; 2013 May; 19(9):2460-72. PubMed ID: 23444225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GULP1 regulates the NRF2-KEAP1 signaling axis in urothelial carcinoma.
    Hayashi M; Guida E; Inokawa Y; Goldberg R; Reis LO; Ooki A; Pilli M; Sadhukhan P; Woo J; Choi W; Izumchenko E; Gonzalez LM; Marchionni L; Zhavoronkov A; Brait M; Bivalacqua T; Baras A; Netto GJ; Koch W; Singh A; Hoque MO
    Sci Signal; 2020 Aug; 13(645):. PubMed ID: 32817372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.